# Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

> **NCT04707300** · PHASE1,PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 10 (estimated)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** Human T Lymphoid Progenitor (HTLP) injection

## Key facts

- **NCT ID:** NCT04707300
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-16
- **Primary completion:** 2026-11
- **Final completion:** 2028-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707300, "Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT04707300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*